MULTI-REGIONAL CLINICAL TRIALS

THE MRCT CENTER of
BRIGHAM AND WOMEN'S HOSPITAL
and HARVARD

A USA perspective on diversity and inclusion

Barbara E. Bierer, MD

Professor of Medicine, Harvard Medical School
Faculty Director, MRCT Center
Director, Regulatory Foundations, Law and Ethics Program, Harvard Catalyst
bbierer@bwh.harvard.edu

3 October 2019   Australian Clinical Trials Conference

Australian
Clinical
Trials
Alliance

Disclaimer:

- The opinions contained herein are those of the authors and are not intended to represent the position of Brigham and Women's Hospital or Harvard University.

- The MRCT Center is supported by voluntary contributions from foundations, corporations, international organizations, academic institutions and government entities (see www.MRCTCenter.org) and well as by grants.

- We are committed to autonomy in our research and to transparency in our relationships. The MRCT Center—and its directors—retain responsibility and final control of the content of any products, results and deliverables.

- We have no personal conflicts of interests with regard to the content of this presentation or discussion.

DEVELOP STANDARDS

ESTABLISH BEST PRACTICES

MULTI-REGIONAL CLINICAL TRIALS
THE MRCT CENTER of BRIGHAM AND WOMEN'S HOSPITAL and HARVARD

IDENTIFY OPPORTUNITIES FOR IMPROVEMENT

IMPROVE TRANSPARENCY

- Academic credibility
- Trusted collaborator
- Independent convener

The MRCT Center is a research and policy center focused on addressing the conduct, oversight, ethics and regulatory environment for clinical trials.

Vision

Improve the integrity, safety, and rigor of global clinical trials.

How we work

Engage diverse stakeholders to define emerging issues in global clinical trials and to create and implement ethical, actionable, and practical solutions.

MRCT Center is affiliated with BWH and Harvard University

BWH BRIGHAM AND WOMEN'S HOSPITAL

HARVARD UNIVERSITY

Agenda

- Introduction to MRCT Center
- Does diversity and inclusion matter?
- Do we (the US) have a problem?

  (By the way, the answer is yes)

- Approaches
- Solving for inclusion

Leadership:
- CAPT Richardae Araojo, FDA
- Barbara E. Bierer, MD, MRCT Center, Harvard
- Luther T. Clark, MD, Merck
- Milena Lolic, FDA
- David H. Strauss, MD, Columbia University

DIVERSITY IN CLINICAL TRIALS

Identifying & addressing barriers

The role of genomics

Why is diversity important?

Case studies and lessons learned

Data collection & analysis considerations

Making the business case

Diversity: a broad interpretation of the term

- Diversity
  - ➢ Demographic
    - Race, ethnicity, ancestry
    - Sex, gender
    - Age
    - Genetics

  - ➢ Non-demographic
    - Co-morbidities
    - Concurrent medications
    - Sexual and gender minorities
    - Differing axes of social determinants of disease
      - Economic status, Environmental factors, Education, Family size, etc.
    - Region (e.g. urban v rural, region and country)
    - Other extrinsic factors

Demographics impact responses to treatment: examples

Demographics (age, sex, race), disease severity, disease duration, PK, comorbidities, concomitant drug use, etc. may affect responses to treatment.

Treatment	Response
BiDil (ISDN/Hydralazine)	VHeFT 1 and VHeFT 2 suggested; AHeFT demonstrated strong benefit in self-identified Blacks with heart failure; Explanation unknown
ACE Inhibitors	Hypertension in Blacks less responsive; Angioedema more common, greater risk
Clopidogrel	Less efficacious in persons with CYP2C19*2 or CYP2C19*3 allele; higher frequencies in East Asians, Native Hawaiians, other Pacific Islanders
Tamoxifen	Subgroup analysis may also be misleading; Original RCT suggested less efficacy in AA women; However, effective equally in AA and White women with ER-positive breast cancer

Not an academic question.
A question of heterogeneity of treatment effect.
A question of social justice and health equity.

Recent public attention, and not good news

Equity, not equality

HEALTHY LIVING 02/23/2017 08:00 am ET | Updated 22 hours ago

Most Clinical Trials Have A Glaring Flaw Before They Even Begin

A lack of diversity in medical studies is hurting science and patients.

By Erin Schumaker

SCIENTIFIC AMERICAN.

POLICY & ETHICS

Clinical Trials Have Far Too Little Racial and Ethnic Diversity

It's unethical and risky to ignore racial and ethnic mi

By THE EDITORS on September 1, 2018

Highlights from
AACR Annual Meeting

Survey: Minorities underrepresented in clinical trials, but want to participate

Black Patients Miss Out On Promising Cancer Drugs

A ProPublica analysis found that black people and Native Americans are under-represented in clinical trials of new drugs, even when the treatment is aimed at a type of cancer that disproportionately affects them.

by Caroline Chen and Riley Wong, Sept. 19, 5 a.m. EDT

Chiara Morra for ProPublica

AAMC
AAMC NEWS

DIVERSITY & INCLUSION

Tuesday, December 20, 2016 | by David Levine and Rebecca Greenberg

More Minorities Needed in Clinical Trials to Make Research Relevant to All

Clinical Trials ARENA
Addressing the key challenges in the global clinical trial space

15 JUNE 2018

We Need to Talk About Race: Lack of Diversity in Clinical Trials is a Public Health Issue

EQUALITY   **EQUITY**

CONQUER

CLINICAL TRIALS MULTIPLE MYELOMA

Lack of Diversity in Clinical Trials Hurts Patients and Drug Development

©MRCT Center

MRCT

5

# Multiple myeloma: Demographics and clinical trial drug development

New Cases of Multiple Myeloma, Per 100,000 People

Race	New Cases
White	6
Black	14
Asian	4
Native American	6

Darzalex

Race	Percent
White	76%
Black	10%
Asian	6%
Native American	Not reported

Empliciti

Race	Percent
White	84%
Black	4%
Asian	10%
Native American	<1%

Farydak

| Race	Percent
White	63%
Black	3%
Asian	33%
Native American	Not reported

Riley Wong for ProPublica Sept. 19, 2018 citing *U.S. Food and Dr Administration; National Cancer Institute*

FDA: Clinically Relevant Enrollment

- FDA expectations are that sponsors enroll participants who reflect the **demographics for clinically relevant population**s with regard to age, gender, race, and ethnicity

- A **plan** to address inclusion of clinically relevant subpopulations should be submitted for discussion to the Agency at the earliest phase of development and, for drugs and biologics, no later than the end of the phase 2 meeting

- Inadequate participation and/or data analyses from clinically relevant subpopulations can lead to insufficient information pertaining to medical product safety and effectiveness for product labeling

How pervasive is the problem?

https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots

Drug Trials Snapshots: Summaries (2015)

	WOMEN	BLACK OR AFRICAN AMERICAN	ASIAN	WHITE	OTHER	AGE 65 AND OLDER	AGE 75 AND OLDER**	AGE 80 AND OLDER**
2015	40%	5%	12%	79%	4%	37%	15%	6%

Including AI/AN, NH/OPI, Unknown/Unreported

Between 2008 and 2013, 21% of new molecular entities approved by FDA, had racial or ethnic (or both) differences in safety, efficacy, pharmacokinetics or pharmacogenomics*

12

*Ramamoorthy A, Pacanowski MA, Bull J, et al: Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther 97:263-273, 2015; Frey WH. https://www.brookings.edu/blog/the-avenue/2018/03/14/the-us-will-become-minority-white-in-2045-census-projects/

* The percentages of the categories "American Indian or Alaska Native (AI/AN)," "Native Hawaiian or Other Pacific Islander (NH/OPI)," and "Unknown/Unreported" were small enough that we combined them into the "Other" category for the purposes of this review.
**These particular subgroups were calculated as part of a Geriatrics Report and are not a regular feature of the Drug Trial Snapshots

Drug Trials Snapshots: Summaries (2015 -2018)

	WOMEN	BLACK OR AFRICAN AMERICAN	ASIAN	WHITE	OTHER	AGE 65 AND OLDER
2015	40%	5%	12%	79%	4%	37%

	WOMEN	BLACK OR AFRICAN AMERICAN	ASIAN	WHITE	OTHER	AGE 65 AND OLDER
2016	48%	7%	11%	76%	7%	21%

	WOMEN	BLACK OR AFRICAN AMERICAN	ASIAN	WHITE	OTHER	AGE 65 AND OLDER
2017	55%	7%	11%	77%	14%	32%

	WOMEN	BLACK OR AFRICAN AMERICAN	ASIAN	WHITE	HISPANIC	AGE 65 AND OLDER
2018	56%	11%	10%	69%	14%	15%

12

* The percentages of the categories "American Indian or Alaska Native (AI/AN)," "Native Hawaiian or Other Pacific Islander (NH/OPI)," and "Unknown/Unreported" were small enough that we combined them into the "Other" category for the purposes of this review.

**These particular subgroups were calculated as part of a Geriatrics Report and are not a regular feature of the Drug Trial Snapshots

Participation of Black/AAs in Clinical Trials for Oncology, Cardiology, and Psychiatry

2.50%
1,415

97.50%
55,118

Cardiovascular Disease
Total Participants = 92,329

2.74%
211

97.26%
7,480

Onocology
Total Participants = 7,691

24.18%
1,405

75.82%
4,405

Psychiatry
Total Participants = 5,810

Black or African American
Some Other Race

13

Individual studies vary widely (2018)

BRAND NAME	INDICATION	WOMEN	WHITE	BLACK or AFRICAN AMERICAN	ASIAN	HISPANIC	AGE 65 and OLDER	UNITED STATES
KRINTAFEL	Prevention of malaria relapse caused by the parasite *Plasmodium vivax*	25%	2%	11%	19%	70%	2%	0%
XERAVA	Treatment of complicated intra-abdominal infections caused by bacteria	43%	98%	< 1	< 1	2%	30%	5%
LUCEMYRA	Treatment of symptoms associated with opioid withdrawal during abrupt opioid discontinuation.	28%	67%	22%	<1	17%	<1	100%

Questions arising

- What are the implications of underrepresentation for science and healthcare?

- How does underrepresentation challenge our notions of fairness/justice?

- What institutional, cultural, logistical, cultural factors are at play?

- Are remedies available and are remedies achievable?

  ➢ Despite the *intention* to recruit diverse and representative study populations in order to detect such differences in drug metabolism, safety profile, or treatment outcome, this does not routinely occur.

  ➢ Challenges including those related to recruitment, enrollment, and obtaining requisite statistical power limit most clinical trials from examining differences by *subgroup*.

Diversity Lacking In Genomic Databases

- Ethnic minorities underrepresented in genomic databases

- Lack of diversity affect understanding of the relationships of genes and disease in un- and under-studied populations

- Significant gaps in knowledge regarding potential health care disparities in genomic medicine and precision health remain

- Genomic databases need greater inclusion of diverse ancestral populations and ancestral information

Genomics and precision medicine may change our understanding of race and its utility in clinical practice and research. However, significant challenges exist that must be overcome for the promise of precision medicine to be realized.

Numbers of genomewide association studies and genotype and phenotype studies, by disease area and study population demographic group, 2017

Legend:
- dbGaP noncancer
- dbGaP cancer
- GWAS noncancer
- GWAS cancer

y-axis: 0, 500, 1,000, 1,500, 2,000, 2,500

x-axis (Study population): European, Asian, Underrepresented minorities

Landry LG, Ali N, Williams DR, Rehm HL, Bonham VL. 37:5 Health Affairs 2018;37:5

A short list of challenges: real and perceived

Regulators/
Institutions/
Sponsors

Investigators/
Referring Physicians

Research Staff

Data & Data
Analysis

Patients//
Communities

- Trial time and cost, inertial forces
- Uncertain scientific utility
- Inaccuracy of feasibility assessments
- Inadequate staffing and time constraints of PIs, staff
- Lack of continuous community engagement
- Recruitment and retention challenges
- Limited health literate communications
- Inclusion/exclusion criteria limiting enrollment
- Trial outcome measures of uncertain participant value
- Logistical issues of trial conduct
- Data collection variable
- Data analysis methodologies inconsistent
- Payment and other concerns
- Mistrust and distrust of research and clinical trials

Barriers, Impediments, Challenges ➡️ Opportunities

Barriers, Impediments

Tools
- Tools
- Infrastructure
- Resources

Knowledge

Motivation
- Incentives
- Disincentives

Metrics
- Metrics
- Transparency

Accountability

Work Group Members

Hayat Ahmed, MRCT Center

Richardae Araojo, FDA (Co-Chai

Salvatore (Salvo) Alesci, Takeda Pharmaceuticals International, Inc.

Maria Apostolaros, PhRMA

Barbara E. Bierer, MRCT Center, Brigham and Women's Hospital, Harvard Medical School (Co-Chair)

Racquel Bruton, Biogen

Elizabeth Cahn, Cancer Connection

Li Chen, Amgen

Luther Clark, Merck (Co-Chair)

Patrick Cullinan, Takeda Pharmaceuticals International, Inc.

Liza Dawson, NIAID/NIH

Theresa R. Devins, Boehringer Ingelheim Pharmaceuticals, Inc.

Anthony Edmonds, Takeda Pharmaceuticals International, Inc.

Rhonda Facile, CDISC

Rachael Fones, IQVIA

Anya Harry, GlaxoSmithKline

Melissa Heidelberg, Genentech/Roche

Quita Highsmith, Genentech/Roche

Aarthi B. Iyer, Kinetiq

Regina James, NIH/NIMHD

Jonathan Jackson, CARE Research Center, Massachusetts General Hospital

Tesheia Johnson, Yale Center for Clinical Investigation

Maria de Leon, DefeatParkinsons

Miiena Lolic, FDA (Co-chair)

Marcia Levenstein, Vivli

Roberto Lewis- Fernández, Columbia University

Eldrin Lewis, Brigham and Women's Hospital

Erin Muhlbradt, NCI-EVS & CDISC

Isabela Niculae, Biogen

Latha Palaniappan, Stanford University

Claude Petit, Boehringer Ingelheim Pharmaceuticals, Inc.

Claire Pigula, Biogen

Melissa Poindexter, Advances in Health

Nicole Richie, Genentech/Roche

Suzanne M. Rivera, Case Western Reserve University

Frank Rockhold, Duke Clinical Research Institute

Ricardo Rojo, Pfizer

Rosanne Rotondo, Novartis

Fabian Sandoval, Emerson Clinical Research Institute

Rick Sax, IQVIA

Hollie Schmidt, Accelerated Cure Project for Multiple Sclerosis

Karlin Schroeder, Parkinson's Foundation

Mary (Dicey) Scroggins, Pinkie Hugs, LLC

Lana Skirboll, Sanofi

Steve Snappin, formerly Amgen

Bhagyashree Sonwane, formerly MRCT Center

Stacy Springs, Bioethics Fellow at Harvard Medical School

David H. Strauss, MRCT Center, Columbia University (Co-Chair)

Sara Tadesse, Genentech/Roche

Anne Taylor, Columbia University Medical Center

Robert A. Winn , University of Illinois Cancer Center

Paul Underwood, Boston Scientific

Sarah White, MRCT Center (Co-Chair)

John Whyte, WebMD (Co-Chair)

Crispin Woolston, Sanofi

Honghui Zhou, Johnson & Johnson

Product Development

Drug Discovery ⟩ Pre-Clinical ⟩ Phase I / Phase 2 ⟩ Phase 3 ⟩ FDA Approval ⟩ Post-Marketing

- When in development phase should diversity be addressed?
- Concerns differ early in development, when little is known, versus Phase 3, versus post-marketing phase
- Real world data and observational studies should be considered in the continuum of understanding of the product
- Development and analysis of heterogeneity of treatment effect should be intentional and planned

# Participant's Clinical Trial Journey

Early(ish) Interventions

Deliverables:

- Statements of commitment
- Education and community engagement resources
- Clear communications
- Feasibility assessment measures
- Patient/participant engagement in trial design and planning
- Eligibility (inclusion/exclusion) criteria
- IRB tool for protocol evaluation

- Case Studies: investigational products, Successful interventions
- Business case(s) for inclusion
   Financial, incentives, disincentives
   Corporate responsibility, public good

Study conduct: Interventions

- Health literate communications and informed consent
- Study design and objectives that are relevant and meaningful to the population
- Logistical changes in study conduct
    - Bringing the trial to the participant (insofar as possible) & site location
    - Minimizing research procedures to absolutely necessary
    - Clinic hours outside of work hours and work days
    - Transportation arrangements
    - Childcare arrangements
    - Payment for reimbursable expenses and for time and burden of study
    - Disability access
    - Mobile technologies
- Post-trial access to medicines as necessary and referral for care
- Return of aggregate study results and, as possible, individual results
- Communication with referring physicians

Transportation

Approach and Potential Solutions

- Problem recognition

- Review of existing transportation options for target populations.

- Ask participants directly about their transportation needs

- If necessary, ensuring access to or provision of reliable transport, including cost

  - Cost (pre-payment or reimbursement)

  - Parking

  - Public transportation (metro-card, vouchers)

  - Taxi (reimbursement)

  - Ride-sharing services

  - Site providing shuttle

  - May extend to family member or friend who will accompany participant

Early
Interventions

Informed consent:
Participant on study

Access

Recruitment
Screening

Awareness

A protocol script for participant needs assessment after enrollment, envisioned as interaction with study coordinator

2019 October

S	M	T	W	T	F	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31		

- How will you get to the clinic for your appointments? Can I help with that?
- Can we look at the calendar together?
- Who lives at home with you?
- Do you have someone that can help you at home?
- Is there someone we can contact if you are not available?
  - LINK to permissions form

End of Study

Later Interventions

Data Analysis
Complete
And Reporting

End of trial
LPLV

Data Lock

Logistical considerations for End of Study:
- End of Study communication
- Post-trial access to medicines, as appropriate
- Referral for further care, as necessary
- Return of aggregate study results and, if/as possible, individual results
- Communication with referring physicians

Data and Data Analysis: Interventions

Data Analysis Complete And Reporting

Data Lock

- International agreement on definition of data elements
- Model methodologies of collection and data entry
  - Templates for data collection
- Genomic data (or samples) collected from diverse populations
- Robust PK/PD studies as indicated
- Development of novel approaches to and methods of data analysis
- Agreement on results reporting
- Commitment to data sharing (aggregate, individual participant data) to allow secondary analyses of pooled datasets
- Post-trial monitoring of real world data
- Research agenda
- Iterative progress

Patient Engagement

- Education
- Engaging patients in trial design and development
- Understanding patient experiences, perceptions, and preferences
- Culturally and linguistically competent strategies
- Community engagement
- Build and consistently maintain trust

12

Comprehensive deliverables

UNDERSTAND
ENGAGE
ACT

MRCT Center

14 Story Street, 4th Floor, Cambridge,
MA 02138, USA
Telephone: (617) 496-9807
Email: mrct@bwh.harvard.edu

Barbara E. Bierer, MD
bbierer@bwh.harvard.edu

Mark Barnes, JD
Mark.Barnes@ropesgray.com

Sarah White, MPH
sawhite@bwh.harvard.edu